Quotient Clinical is pleased to announce that it has successfully completed its first inspection by the US Food and Drug Administration (FDA). The inspection took place on 7 – 11 December 2015 and focused on a clinical bioequivalence study conducted for a Sponsor at Quotient’s clinical facility in Nottingham, UK, with no Form 483 observations issued.
Mark Egerton, Chief Executive Officer of Quotient Clinical, commented: “this positive endorsement by the FDA reinforces our commitment to high quality clinical research for a global customer base and adds to our long outstanding audit history with UK regulator the MHRA.”